Arabic Arabic English English French French German German
dark

PDS Biotechnology Appoints Immuno-Oncology Experts Dr. Olivera Finn and Dr. Mark Frohlich to Scientific Advisory Board

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® T-cell activating technology, today announced the appointment of Dr. Olivera Finn and Dr. Mark Frohlich to its Scientific Advisory Board. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

OAG report into vaccine programme ‘useful and timely’ says Ministry

Next Post

Kelyniam Global Releases Q1 Financial Results – Profitability Despite the 2nd Wave Pandemic

Related Posts
Total
0
Share